These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 16704803)

  • 1. Prospects for universal influenza virus vaccine.
    Gerhard W; Mozdzanowska K; Zharikova D
    Emerg Infect Dis; 2006 Apr; 12(4):569-74. PubMed ID: 16704803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospects for broadly protective influenza vaccines.
    Treanor JJ
    Vaccine; 2015 Nov; 33 Suppl 4():D39-45. PubMed ID: 26338145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza vaccine--outmaneuvering antigenic shift and drift.
    Treanor J
    N Engl J Med; 2004 Jan; 350(3):218-20. PubMed ID: 14724300
    [No Abstract]   [Full Text] [Related]  

  • 4. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.
    Bianchi E; Liang X; Ingallinella P; Finotto M; Chastain MA; Fan J; Fu TM; Song HC; Horton MS; Freed DC; Manger W; Wen E; Shi L; Ionescu R; Price C; Wenger M; Emini EA; Cortese R; Ciliberto G; Shiver JW; Pessi A
    J Virol; 2005 Jun; 79(12):7380-8. PubMed ID: 15919893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity.
    Belshe RB; Coelingh K; Ambrose CS; Woo JC; Wu X
    Vaccine; 2010 Feb; 28(9):2149-56. PubMed ID: 20003926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Universal influenza vaccine: the holy grail?
    Shaw AR
    Expert Rev Vaccines; 2012 Aug; 11(8):923-7. PubMed ID: 23002973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A DNA vaccine expressing PB1 protein of influenza A virus protects mice against virus infection.
    Košík I; Krejnusová I; Práznovská M; Poláková K; Russ G
    Arch Virol; 2012 May; 157(5):811-7. PubMed ID: 22294447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Universal influenza vaccines: developments, prospects for use].
    Tsybalova LM; Kiselev OI
    Vopr Virusol; 2012; 57(1):9-14. PubMed ID: 22624467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa.
    Brokstad KA; Eriksson JC; Cox RJ; Tynning T; Olofsson J; Jonsson R; Davidsson A
    J Infect Dis; 2002 Apr; 185(7):878-84. PubMed ID: 11920311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Learning from the 2009 H1N1 pandemic: prospects for more broadly effective influenza vaccines.
    Settembre EC; Dormitzer PR; Rappuoli R
    J Mol Cell Biol; 2011 Jun; 3(3):144-6. PubMed ID: 21430014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The antigenic-immunogenic activity of the trivalent polymer-subunit influenza vaccine Grippol in a controlled epidemiological trial (2)].
    El'shina GA; Masalin IuM; Shervarli VI; Gorbunov MA; Lonskaia NI; Agafonova LV; Khaitov RM; Nekrasov AV; Ivanova AS
    Voen Med Zh; 1996 Nov; 317(11):53-5. PubMed ID: 9036633
    [No Abstract]   [Full Text] [Related]  

  • 12. Novel Platforms for the Development of a Universal Influenza Vaccine.
    Kumar A; Meldgaard TS; Bertholet S
    Front Immunol; 2018; 9():600. PubMed ID: 29628926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection abilities of influenza B virus DNA vaccines expressing hemagglutinin, neuraminidase, or both in mice.
    Fang F; Cai XQ; Chang HY; Wang HD; Yang ZD; Chen Z
    Acta Virol; 2008; 52(2):107-12. PubMed ID: 18564897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The immunogenic properties and prophylactic efficacy of a live polyvalent influenza vaccine in children 5 to 14 years old].
    Grigor'eva EP; Rekstin AR; Rudenko LG; Ramirez A; Barro M; Lisovskaia KV; Klimov AI; Aleksandrova GI
    Vopr Virusol; 1994; 39(1):26-9. PubMed ID: 8160445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses.
    Li S; Liu C; Klimov A; Subbarao K; Perdue ML; Mo D; Ji Y; Woods L; Hietala S; Bryant M
    J Infect Dis; 1999 May; 179(5):1132-8. PubMed ID: 10191214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing perspective on immunization against influenza.
    Johansson BE; Brett IC
    Vaccine; 2007 Apr; 25(16):3062-5. PubMed ID: 17276554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in development of the influenza vaccine with broader cross-protection.
    Stropkovská A; Janulíková J; Varecková E
    Acta Virol; 2010; 54(1):7-19. PubMed ID: 20201609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza virus hemagglutinin stalk-based antibodies and vaccines.
    Krammer F; Palese P
    Curr Opin Virol; 2013 Oct; 3(5):521-30. PubMed ID: 23978327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Influenza season 2007/'08 in the Netherlands: antigenic variation, oseltamivir resistance and vaccine composition for the 2008/'09 season].
    Rimmelzwaan GF; de Jong JC; Donker GA; Meijer A; Fouchier RA; Osterhaus AD
    Ned Tijdschr Geneeskd; 2008 Sep; 152(39):2138-44. PubMed ID: 18856032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimates of influenza vaccine effectiveness for 2007-2008 from Canada's sentinel surveillance system: cross-protection against major and minor variants.
    Janjua NZ; Skowronski DM; De Serres G; Dickinson J; Crowcroft NS; Taylor M; Winter AL; Hottes TS; Fonseca K; Charest H; Drews SJ; Sabaiduc S; Bastien N; Li Y; Gardy JL; Petric M
    J Infect Dis; 2012 Jun; 205(12):1858-68. PubMed ID: 22492921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.